UK medicines regulator sets out 2030 strategy for AI and patient safety
The UK’s medicines regulator published a 2030 strategy October 14 covering patient involvement, safety surveillance, AI and changes to regulatory services.
What the record says
MHRA announcement dated October 14, 2026.
The strategy covers regulation and patient safety across all four UK nations.
A medicines-development AI action plan is planned for 2027.
MHRA’s commitments include making Yellow Card adverse-event reporting simpler, developing an AI-enabled clinical-trial protocol checker and establishing a Centre for AI and Digital Health. The strategy also proposes a higher-value scientific-advice service with a 45-day target instead of 90 days, and a 14-day initial-assessment target for qualifying Phase 1 trials. An AI Medicines Development Action Plan is planned for 2027.
Source details and supporting locations.
Practical next step
Read MHRA’s strategy announcement for its commitments and planned implementation. Continue to use existing official reporting routes for suspected medicine or device problems.
Limits and what is not established
The announcement sets out a strategy and targets. It does not prove that new services are already available, shorten every trial’s approval time or establish that any AI product is safe or approved.
Sources checked October 14, 2026. Later notices may change instructions or arrangements.
Original sources
UK Medicines and Healthcare products Regulatory Agency: original information